Literature DB >> 22977410

Long-acting beta(2)-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: systematic review of clinical outcomes and economic evaluation.

.   

Abstract

Year:  2010        PMID： 22977410      PMCID： PMC3411155     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN： 1203-9012


× No keyword cloud information.
  79 in total

1.  Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.

Authors:  T van der Molen; D S Postma; M O Turner; B M Jong; J L Malo; K Chapman; R Grossman; C S de Graaff; R A Riemersma; M R Sears
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

2.  Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone.

Authors:  Anne Mette Strand; Anders Luckow
Journal:  Respir Med       Date:  2004-10       Impact factor: 3.415

3.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Authors:  Paul M O'Byrne; Hans Bisgaard; Philippe P Godard; Massimo Pistolesi; Mona Palmqvist; Yuanjue Zhu; Tommy Ekström; Eric D Bateman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

4.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

Authors:  R A Pauwels; C G Löfdahl; D S Postma; A E Tattersfield; P O'Byrne; P J Barnes; A Ullman
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

5.  Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.

Authors:  John Murray; Richard Rosenthal; Laura Somerville; Kathryn Blake; Karen House; Leslie Baitinger; Anna VanderMeer; Paul Dorinsky
Journal:  Ann Allergy Asthma Immunol       Date:  2004-10       Impact factor: 6.347

6.  Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

Authors:  J P Kemp; D A Cook; G A Incaudo; J Corren; C Kalberg; A Emmett; F M Cox; K Rickard
Journal:  J Allergy Clin Immunol       Date:  1998-02       Impact factor: 10.793

7.  Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma.

Authors:  S Langton Hewer; J Hobbs; D French; W Lenney
Journal:  Respir Med       Date:  1995-07       Impact factor: 3.415

8.  Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.

Authors:  G Boyd
Journal:  Eur Respir J       Date:  1995-09       Impact factor: 16.671

9.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.

Authors:  A P Greening; P W Ind; M Northfield; G Shaw
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

10.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.

Authors:  A Woolcock; B Lundback; N Ringdal; L A Jacques
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405
View more
  8 in total

1.  Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.

Authors:  M Diane Lougheed; Catherine Lemiere; Francine M Ducharme; Chris Licskai; Sharon D Dell; Brian H Rowe; Mark Fitzgerald; Richard Leigh; Wade Watson; Louis-Philippe Boulet
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

Review 2.  The nature and influence of pharmaceutical industry involvement in asthma trials.

Authors:  Ken Bond; Carol Spooner; Lisa Tjosvold; Catherine Lemière; Brian H Rowe
Journal:  Can Respir J       Date:  2012 Jul-Aug       Impact factor: 2.409

3.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

Review 4.  Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma.

Authors:  Lisa Hartling; Kenneth Bond; Ben Vandermeer; Jennifer Seida; Donna M Dryden; Brian H Rowe
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

5.  Factors associated with relapse in adult patients discharged from the emergency department following acute asthma: a systematic review.

Authors:  Jesse Hill; Nicholas Arrotta; Cristina Villa-Roel; Liz Dennett; Brian H Rowe
Journal:  BMJ Open Respir Res       Date:  2017-01-27

6.  A systematic review of methodology used in the development of prediction models for future asthma exacerbation.

Authors:  Joshua Bridge; John D Blakey; Laura J Bonnett
Journal:  BMC Med Res Methodol       Date:  2020-02-05       Impact factor: 4.615

7.  One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.

Authors:  Kenneth Chapman; Richard van Zyl-Smit; Jorge Maspero; Huib A M Kerstjens; Yasuhiro Gon; Motoi Hosoe; Ana-Maria Tanase; Abhijit Pethe; Xu Shu; Peter D'Andrea
Journal:  BMJ Open Respir Res       Date:  2021-08

8.  Identifying Drug-Therapy Problems among Syrian Refugees in Zaatari Refugee Camp.

Authors:  Alaa M Hammad; Walid Al-Qerem; Fawaz Alasmari; Jonathan Ling; Raghda Qarqaz; Hakam Alaqabani
Journal:  Int J Environ Res Public Health       Date:  2022-06-12       Impact factor: 4.614
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.